Neurogene Q3 net loss $20.2M; positive NGN-401 data; $200M private placement

Neurogene Inc.

2024-Q3 EPS reported -$3.29 revenue$925,000

Q3 net loss $20.2M vs $14.6M YoY; cash & investments $139M as of Sep 30, 2024.
First 4 NGN-401 participants at 1E15 vg showed consistent improvements; 28-52% RSBQ improvement.
SAE at 3E15 vg dose; FDA allows continued enrollment at 1E15 vg; enrollment paused for protocol revision.
NGN-101 CLN5 Batten program discontinued after RMAT application denied; options being evaluated.
Closed ~$200M private placement extending cash runway into second half of 2027.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.